WEST LAFAYETTE, Ind. — Eradivir, a preclinical biotech company, has developed a patent-pending antiviral therapeutic that reduces lung viral loads of advanced-stage influenza in preclinical studies ...

The use of the recombinant influenza vaccine can prevent a substantial number of influenza-related hospitalizations among adults in the United States who have chronic conditions.